Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8529159 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30924861 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30361178 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30562167 | 0.91 | DPP4 (0.51) | DPP4DPP8DPP9PDCD1LG2CD274 | |
| SCHEMBL31688167 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29539434 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29816159 | 0.89 | BACE1 (0.53) | DPP4DPP8DPP9CTSDBACE1 | |
| SCHEMBL30997362 | 0.89 | BACE1 (0.53) | DPP4DPP8DPP9CTSDBACE1 | |
| SCHEMBL5970526 | 0.89 | DPP4 (0.58) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL4388337 | 0.89 | DPP4 (0.58) | DPP4DPP8DPP9CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132725-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF INTRACRANIAL HEMORRHAGIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF INTRACRANIAL HEMORRHAGIC STROKE FROM ACUTE ISCHEMIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | claimed |
| US-20240158448-A1 | MULTIVALENT NANO-'SELF' PEPTIDES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | claimed |
| CN-114032271-B | Oyster polypeptide and polypeptide powder with uric acid reducing effect, and preparation method and application thereof | 浙江工业大学 | 2024-03-26 | — | — | CN | claimed |
| WO-2022178263-A1 | MULTIVALENT NANO-'SELF' PEPTIDES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-08-25 | — | — | WO | claimed |
| CN-114032271-A | Oyster polypeptide and polypeptide powder with uric acid reducing effect as well as preparation method and application of oyster polypeptide and polypeptide powder | 浙江工业大学 | 2022-02-11 | — | — | CN | claimed |
| CN-109311927-A | Sugar-dipeptides conjugates as flavor molecules | 雀巢产品技术援助有限公司 | 2019-02-05 | — | — | CN | claimed |
| WO-2016112174-A2 | Biomarkers of Sleep Deprivation and Cognitive Impairment | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-07-14 | — | — | WO | claimed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| WO-2026107381-A1 | DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260062697-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | MODERNATX INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250215086-A1 | ANTI-PD-1 ANTIBODY FORMULATIONS | AMGEN INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130115649-A1 | Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same | METABOLON, INC. | 2013-05-09 | — | — | US | disclosed |
| US-20120208215-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8187830-B2 | Method for determining insulin sensitivity with biomarkers | METABOLON, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090155826-A1 | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same | METABOLON, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158448-A1 | MULTIVALENT NANO-'SELF' PEPTIDES AND USES THEREOF | CD47, CD68, CHERP | DPP4 3432/4885DPP8 3949/4885DPP9 3354/4885 |
| US-20260062697-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | UPF1, METTL16, RNGTT | DPP4 3732/4885DPP8 1876/4885DPP9 2934/4885 |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | HBB, HBG1, HBG2 | DPP4 3709/4885DPP8 2999/4885DPP9 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.